Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9444531 | 0.73 | SLC6A3 (0.36) | LMNATSHR | |
| SCHEMBL818627 | 0.70 | SLC6A3 (0.41) | ALDH1A1 | |
| SCHEMBL818444 | 0.69 | TSHR (0.39) | LMNATSHRALDH1A1MAPTCA12 | |
| SCHEMBL818541 | 0.68 | NPSR1 (0.32) | SMN1; SMN2LMNATSHRALDH1A1USP2 | |
| SCHEMBL818180 | 0.66 | SLC6A3 (0.33) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL817433 | 0.66 | SLC6A3 (0.33) | — | |
| SCHEMBL12808601 | 0.65 | NPSR1 (0.31) | ALDH1A1 | |
| SCHEMBL818744 | 0.65 | KDM4E (0.31) | SMN1; SMN2LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL19446735 | 0.64 | TDP1 (0.34) | SMN1; SMN2TSHRCA12CA1CA2 | |
| SCHEMBL30564905 | 0.64 | NPSR1 (0.34) | LMNATSHRGSK3AGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2022238737-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | WO | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-09-08 | — | — | US | disclosed |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (HK) | 2022-04-05 | — | — | US | disclosed |
| WO-2021097243-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | SNCA, PARK7, PRNP | SMN1; SMN2 13/4885LMNA 1209/4885TSHR 4699/4885 |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | SMN1; SMN2 13/4885LMNA 1209/4885TSHR 4699/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | SMN1; SMN2 191/4885LMNA 1837/4885TSHR 4439/4885 |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | SMN1; SMN2 16/4885LMNA 1339/4885TSHR 4677/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | SMN1; SMN2 188/4885LMNA 1930/4885TSHR 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.